ArticleCureus2025
Long-Term Arteriovenous Access Clinical Patency Following Successful Thrombolysis: A Single-Centre Experience.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction There is a paucity of data regarding the long-term outcomes following thrombolysis of arteriovenous (AV) access for dialysis. The aim was to determine the technical and clinical success following thrombolysis of a thrombosed AV access and the long-term clinical patency and access survival in our institution. Methods Retrospective identification of all patients undergoing thrombolysis of an AV access, AV fistula (AVF), or graft (AVG) over eight years at a single institution. Patient characteristics, access type, type of thrombolysis, and fistula life were recorded. Data were censored for death, transplantation, and loss to follow-up. Results Ninety-eight vascular accesses (79 AVF and 19 AVG) in 94 patients underwent thrombolysis during the study period. Fifty-three (56.4%) were male with a median (interquartile range [IQR]) age of 66 (53-74) years. Immediate technical and clinical success were 82% and 75%, respectively. Clinical patency following clinically successful thrombolysis at three, six, and 12 months was 64.5%, 60%, and 45.9%, respectively. At two and three years, clinical patency was 21.3% and 7.9%, respectively. AVFs were older than AVGs, 96 (44-192) vs. 20 (12-76) months, p<0.0001 at the time of thrombolysis. 21% of AV accesses that had successful thrombolysis and restoration of clinical patency re-presented with thrombosis after a median (IQR) of 185 (93.5-358) days and underwent further thrombolysis. AVGs (47.4%) were more likely to have re-thrombosed after successful thrombolysis than AVFs (15.2%), p=0.002. Kaplan-Meier survival analysis demonstrated that AVFs remained patent for longer than AV grafts (p=0.023) following successful thrombolysis. While in the short term, clinical patency was re-established, overall, there was no AV access survival advantage (p=0.085) over those that only required one episode of thrombolysis to restore access patency. Conclusions Endovascular strategies for dealing with thrombosed access are clinically important in allowing haemodialysis to continue. However, the clinical patency rates, while good in the short term, fail to be sustained long term. We propose that an episode of AV access thrombosis and successful thrombolysis should prompt a review of previous access-related interventions, age of AV access, and planning for alternative AV access options, be it new AV access formation, transplant, or long-term catheter placement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.